Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

OXERVATE eye drops show promise for Long-Term corneal healing in rare eye disease

NCT ID NCT05552261

Disease control Sponsor: Dompé Farmaceutici S.p.A Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 24 people with stage 1 neurotrophic keratitis, a rare eye condition that can damage the cornea, who had previously used OXERVATE eye drops in an earlier study. Researchers checked if the cornea stayed healed up to 30 months after treatment. The goal was to see if the medicine's effects last long-term and to monitor safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cenegermin (OXERVATE) eye drops
What this could lead to
If successful, this could show that OXERVATE helps maintain corneal healing for up to 30 months in people with neurotrophic keratitis.
What could go wrong
This is a small extension study with only 24 participants and no new treatment given, so results may not apply to everyone. Long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

24 people

The number who actually took part.

Started

Feb 2023

Finished

Apr 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Stage 1 NK

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Previously enrolled in the DEFENDO Study. 2. Satisfied all Informed Consent requirements. The patient and/or their legal representative read, signed, and dated the IRB approved Informed Consent document before any study-related procedures were performed. 3. Had the ability and willingness to comply with study procedures. Exclusion Criteria: Were participating in another study that involved treating the study eye. Participation in non-ocular studies was acceptable provided that the treatment was not considered to be confounding with the DEFENDO Long-Term Follow-up Study, in the opinion of the Investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurotrophic keratitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neurotrophic keratopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neurotrophic keratitis

Contacts and locations

Locations

  • Cincinnati Eye Institute

    Edgewood, Kentucky, 41017, United States

  • New Vision Institute

    San Diego, California, 92037, United States

  • Scheie Eye Institute

    Philadelphia, Pennsylvania, 19104, United States

  • Tufts Medical Center

    Boston, Massachusetts, 02011, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.